Progressive spinal cord atrophy in manifest and premanifest Huntington's disease.

Competing Interests: Competing interests: RG has received honoraria, consultant fees or other support from Baxter, Bayer Schering, Biogen Idec, CLB, Behring, Genzyme, Merck Serono, Novartis, Talecris, Teva and Wyeth. CS reports grants from Teva Endowed Professorship, grants from 'Cure Huntington's Disease Initiative´ (CHDI), grants from Biogen, personal fees from Temmler Pharma GmbH & Co. KG, personal fees from Desitin Arzneimittel GmbH, outside the submitted work; and CS received institutional compensation and/or travel or accommodation payments in the context of the ENROLL-Study (CHDI), Registry-Study of the Euro-HD-Network, in the context of the MitoNet-study, the ACR16-Study (Neurosearch), the AFQ-Study (Novartis), the Selisistat-Studies (Siena Biotech), the PRIDE-HD- and LEGATO-HD-Study (TEVA), the Amaryllis-Study (Pfizer) and in context of the IONIS 443139-CS1 Study. CL has received consulting and speaker's honoraria from BiogenIdec, Bayer Schering, Novartis, Sanofi, Genzyme and TEVA, and has received research scientific grant support from Bayer Schering, TEVA and MerckSerono. He holds an endowed professorship supported by the Novartis Foundation.